Royal Bank of Canada Has $7.41 Million Stock Holdings in The Chemours Company $CC

Royal Bank of Canada trimmed its position in shares of The Chemours Company (NYSE:CC) by 12.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 336,365 shares of the specialty chemicals company’s stock after selling 47,808 shares during the period. Royal Bank of Canada owned approximately 0.22% of Chemours worth $7,410,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Atlas Capital Advisors Inc. acquired a new stake in shares of Chemours during the 4th quarter worth approximately $26,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Chemours in the fourth quarter valued at $28,000. Covestor Ltd lifted its position in Chemours by 204.7% in the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company’s stock worth $31,000 after purchasing an additional 1,748 shares during the period. Eurizon Capital SGR S.p.A. bought a new position in Chemours in the fourth quarter worth $31,000. Finally, Rothschild Investment LLC boosted its stake in Chemours by 87.0% during the fourth quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock worth $32,000 after buying an additional 1,255 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Price Performance

NYSE:CC opened at $14.52 on Tuesday. The firm has a market cap of $2.19 billion, a PE ratio of -7.60 and a beta of 1.43. The Chemours Company has a 12 month low of $10.44 and a 12 month high of $28.67. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98. The company’s 50-day moving average price is $19.08 and its two-hundred day moving average price is $20.05.

Chemours (NYSE:CC) last issued its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.07). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.65 billion. Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.Chemours’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.54) earnings per share. On average, equities analysts anticipate that The Chemours Company will post 0.91 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 14th will be given a dividend of $0.0875 per share. The ex-dividend date is Friday, August 14th. This represents a $0.35 dividend on an annualized basis and a yield of 2.4%. Chemours’s dividend payout ratio is -18.32%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CC. Morgan Stanley set a $18.00 price target on shares of Chemours in a report on Monday. Weiss Ratings lowered shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday. UBS Group reissued a “neutral” rating and issued a $18.00 target price (down from $29.00) on shares of Chemours in a research note on Monday. Mizuho set a $22.00 price target on shares of Chemours in a research note on Wednesday, August 5th. Finally, Alembic Global Advisors reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Chemours in a report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Insider Buying and Selling

In other Chemours news, CFO Shane Hostetter purchased 3,350 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average cost of $14.94 per share, with a total value of $50,049.00. Following the acquisition, the chief financial officer directly owned 102,698 shares of the company’s stock, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.85% of the stock is currently owned by company insiders.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.